Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity
Study Details
Study Description
Brief Summary
The main objective of this observatory is to evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This observatory evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity, after a one-month treatment with Bibidobacterium longum 35624, 1x10^9 CFU/capsule, 1 capsule/day.
Study Design
Outcome Measures
Primary Outcome Measures
- Quality of life assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL). [Assessed at baseline and after 1 month of treatment]
Change from baseline of quality of life as assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL, scoring from 0 to 100, with higher scores indicating better IBS specific quality of life) in IBS patients having different subtypes of transit pattern and different level of symptom severity.
Secondary Outcome Measures
- Quality of life subscores assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL). [Assessed at baseline and after 1 month of treatment]
Change from baseline of quality of life subscores as assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL, scoring from 0 to 100, with higher scores indicating better IBS specific quality of life) in IBS patients having different subtypes of transit pattern and different level of symptom severity.
- IBS Symptom Severity [Assessed at baseline and after 1 month of treatment]
Change of IBS Symptom Severity assessed with the IBS Severity Scoring System (IBS-SSS, scoring from 0 to 500, with higher scores indicating worse severity of IBS symptoms)
- Change of Stool consistency [Assessed at baseline, day10, day 20 and day 30]
Change of stool consistency assessed with the Bristol stool scale. The Bristol Stool Chart classifies stool according to their shape and consistency and assigns a sample a number from 1-7 depending on its characteristics, corresponding to constipation normal or diarrhea.
- Compliance to the treatment [Assessed after 1 month of treatment]
Compliance assessed with patient self-report on a diary
- Patient satisfaction [Assessed after 1 month of treatment]
Patient satisfaction with treatment assessed on a 5-point Likert scale, with proposals ranked in ascending order of satisfaction as 1- Not at all satisfied; 2- Unsatisfied; 3- Somewhat satisfied; 4-Satisfied to 5-Very satisfied
- Patient's overall impression after treatment [Assessed after 1 month of treatment]
The patient's overall impression of how the product has changed his or her daily activities, symptoms, and quality of life, assessed with the Patients' Global Impression of Change (PGIC) scale. PGIC is a 7-point scale describing patient's rating of overall improvement. Change is rated by patients as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
- Physician's satisfaction [Assessed after 1 month of treatment]
Physician satisfaction with the treatment for his/her patient assessed on a 5-point Likert scale, with proposals ranked in ascending order of satisfaction as 1- Not at all satisfied; 2- Unsatisfied; 3- Somewhat satisfied; 4-Satisfied to 5-Very satisfied
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female, at least 18 years of age
-
Gastroenterology consultation for an Irritable Bowel Syndrome according to Rome IV criteria
-
Having received a first prescription of Bifidobacterium longum 35624 during the consultation (independently of participation in the observatory)
-
Informed and having declared his/her non-opposition to the study.
Exclusion Criteria:
-
Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook
-
Having already taken Bifidobacterium longum 35624
-
Having received probiotics or antibiotics within 2 weeks previous
-
Having started within the last 7 days a treatment that can interfere with the investigator's evaluation of the investigational product under investigation
-
Participant in another trial
-
Pregnant or breastfeeding women
-
Being under guardianship or curator.
-
Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Avicenne | Bobigny | France | 93009 |
Sponsors and Collaborators
- Biocodex
Investigators
- Study Director: Gyasi K Johnson, PhD, Biocodex
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Floravie